Posters & Presentations – Page 4

Sep 16th 2025

Derivation of Excess Lifetime Cancer Risk via the Oral Route of Exposure

As there are a variety of oral nicotine products on the market, the focus herein is on a method for calculating both non-cancer hazards (HQ/HI) and ECLR for oral tobacco products based on FDA’s equations for adjusted toxicity factors and utilizing CORESTA reference product data (CRP1.1 and CRP2.1)3 for demonstration purposes.

Sep 4th 2025

Updating Scope of ISO 21766:2021, Tobacco and tobacco products – Determination of tobacco-specific nitrosamines in tobacco products – Method using LC-MS/MS to include nicotine pouches

Proposal is to execute a collaborative study using a combination of method parameters from Swedish Match and RAIS, assess the results reported from participating labs, and make a recommendation for either amending ISO 27166:2021 or creation of a new standard.

Jun 17th 2025

Modern Oral Nicotine Pouches: Abuse Liability and Nicotine Pharmacokinetics Assessed in Two Randomized Crossover Clinical Studies

Similar to NRT gum, Velo Pouches and Mini Pouches demonstrate low risk of abuse compared with usual brand cigarettes and may provide levels of nicotine that enable some adult cigarette smokers to transition away from smoking to use of the Velo pouches.

Jun 5th 2025

Impact of flavors in switching smokers: Vuse Alto Menthol

Large proportions of current cigarette smokers would only purchase Alto Menthol. Research suggests removal of flavored products from the market would result in some users returning to cigarette use.

Apr 15th 2025

Consumer Driven Real-World Data: The Vuse Alto Story

46% of the population of vapor purchasers who switched from cigarettes purchased Alto Menthol vs Alto Tobacco (25.6%), Market Comparator Tobacco (3.0%), and Market Comparator Menthol (2.5%).

Oct 10th 2024

Experimental Design and Results from Non-Targeted Analyses of glo Heated Tobacco Products

Overall, this study finds that glo HTP aerosols contain fewer and significantly lower levels of constituents than combustible cigarette smoke. Toxicological reviews determined that the overall toxicological impact of glo HTP aerosol exposure on the consumer is likely to be less than that of combustible cigarette smoke, consistent with supporting in vitro data. Study results are consistent with the abundance of chemistry, non-clinical toxicology, and clinical data submitted to FDA, supporting a conclusion that the use of glo HTPs is likely to present substantially less harm to individuals than cigarette smoking.

Oct 10th 2024

End-to-End Review of ENDS Product PMTA Science Package: Vuse Case Study

This study presents evidence on Vuse Alto and its potentially reduced risks compared to combustible cigarettes.

Sep 9th 2024

Topography Study of glo Hyper, a Tobacco Heated Product

Topography is useful in assessing the health risk of a tobacco product by measuring how a user consumes a product.

Sep 9th 2024

Velo Nicotine Pouch Use Behaviors and Smoking Reduction among U.S. Adult Smokers With and Without Intentions to Quit Smoking

Behavior results from this study suggest that the availability of Velo pouch products may contribute positively to public health by decreasing cigarette consumption, regardless of expressed quit intention.